- Home
- TRIP vs SANA Comparison
TRIP vs SANA Comparison
Compare TRIP & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TRIP | SANA |
|---|---|---|
| Founded | 2000 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2011 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TRIP | SANA |
|---|---|---|
| Price | $14.54 | $4.05 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 7 |
| Target Price | ★ $15.88 | $7.83 |
| AVG Volume (30 Days) | 2.2M | ★ 4.9M |
| Earning Date | 02-19-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 124.53 | N/A |
| EPS | ★ 0.59 | N/A |
| Revenue | ★ $1,891,000,000.00 | N/A |
| Revenue This Year | $5.18 | N/A |
| Revenue Next Year | $4.97 | N/A |
| P/E Ratio | $24.86 | ★ N/A |
| Revenue Growth | ★ 4.25 | N/A |
| 52 Week Low | $10.43 | $1.26 |
| 52 Week High | $20.16 | $7.30 |
Technical Indicators
Market Signals| Indicator | TRIP | SANA |
|---|---|---|
| Relative Strength Index (RSI) | 48.26 | 41.63 |
| Support Level | $13.76 | $4.40 |
| Resistance Level | $14.81 | $4.73 |
| Average True Range (ATR) | 0.47 | 0.29 |
| MACD | 0.01 | -0.10 |
| Stochastic Oscillator | 39.95 | 8.74 |
Price Performance
Historical ComparisonAbout TRIP TripAdvisor Inc.
Tripadvisor is the world's leading travel metasearch company. Its platform offers 1 billion reviews and information on several million accommodations, restaurants, experiences, airlines, and cruises. In 2024, 52% of revenue came from the company's core Brand Tripadvisor segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 46% of revenue in 2024, and TheFork, its dining brand, represented 10% of sales (about 8% of revenue were intersegment, which are eliminated from consolidated revenue).
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.